Servier, founded in 1954, is the first French independent pharmaceutical group. We are present in 148 countries, with more than 21 600 employees, including 2800 in R&D.
Servier, in Collaboration with Allogene Therapeutics, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T Therapy
Servier and Neurochlore launch phase 3 studies in Europe to evaluate bumetanide in children suffering from Autism Spectrum Disorders
> All News
